Friday, October 16, 2026

ON Semiconductor Guides AI Data Center Revenue to Double in 2026 After Stock Surges 60%

ON Semiconductor issued guidance for AI data center revenue to double year-over-year in 2026, following a Q1 2026 earnings beat that drove a 60.1% stock surge over three months. The guidance signals accelerating demand for specialized chips powering AI infrastructure. Rising Treasury yields are tightening conditions broadly, but high-growth AI hardware names are proving resilient.

LM Salvado

May 20, 2026

ON Semiconductor Guides AI Data Center Revenue to Double in 2026 After Stock Surges 60%
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

ON Semiconductor guided AI data center revenue to double year-over-year in 2026, one of the most aggressive growth targets issued by a major chip supplier this cycle.1

The company's stock surged 60.1% over three months following its Q1 2026 earnings beat.1 That outperformance reflects a broader market repricing of semiconductor companies with direct AI infrastructure exposure.

AI data centers require power management chips, silicon carbide components, and intelligent sensing solutions — all areas where ON Semiconductor competes. The doubling guidance implies the company is seeing sustained order momentum from hyperscaler and cloud customers building out AI compute capacity.

Financial conditions are tightening in parallel. The 10-Year US Treasury benchmark rose from 4.31 to 5.0, a move that typically compresses equity valuations.1 High-growth AI hardware names have so far proven an exception, as investors treat AI infrastructure spending as non-discretionary.

Convertible debt markets are also shifting. ON Semiconductor's 2.50% Convertible Senior Notes saw a sharp repricing, with the relevant parameter dropping from 75.0 to 3.72 — consistent with restructuring activity seen across AI-adjacent balance sheets as companies optimize capital structures for a higher-rate environment.1

The divergence between AI-specific semiconductor names and the broader chip sector is becoming measurable. Companies with direct AI data center revenue lines — ON Semiconductor and Nvidia among them — are posting growth trajectories that general semiconductor indices are not matching. Whether that gap widens through Q3 2026 will depend on whether hyperscaler capex commitments translate into sustained silicon orders or front-loaded buying.

ON Semiconductor's doubled revenue guidance is the clearest public signal yet that AI hardware infrastructure investment has moved beyond early adoption into a sustained, multi-year buildout phase.

In this story

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
ON Semiconductor Guides AI Data Center Revenue to Double in 2026 After Stock Surges 60% | Via News